Asset Details
Do you wish to reserve the book?
Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics
Do you wish to request the book?
Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics
2021
Overview
Background
Mitochondrial fission regulator 2 (MTFR2) was involved in the progression and development of various cancers. However, the relationship between MTFR2 with lung adenocarcinoma (LUAD) had not been reported. Herein, this study analyzed the clinical significance and potential mechanisms of MTFR2 in LUAD via bioinformatics tools.
Results
We found that the level of MTFR2 was increased, and correlated with sex, age, smoking history, neoplasm staging, histological subtype and TP53 mutation status in LUAD patients. Kaplan-Meier survival analysis showed LUAD patients with increased MTFR2 had a poor prognosis. In addition, univariate COX regression analysis showed neoplasm staging, T stage, distant metastasis and MTFR2 level were risk factors for the prognosis of LUAD. A total of 1127 genes were coexpressed with MTFR2, including 840 positive and 208 negative related genes. KEGG and GSEA found that MTFR2 participated in the progression of LUAD by affecting cell cycle, DNA replication, homologous recombination, p53 signaling pathway and other mechanisms. The top 10 coexpressed genes, namely CDK1, CDC20, CCNB1, PLK1, CCNA2, AURKB, CCNB2, BUB1B, MAD2L1 and BUB1 were highly expressed, and were associated with poor prognosis in LUAD.
Conclusions
Consequently, we elucidated MTFR2 was a biomarker for diagnosis and poor prognosis in LUAD, and might participate in the progression of LUAD via affecting cell cycle, DNA replication, homologous recombination and p53 signaling pathway.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adenocarcinoma of Lung - diagnosis
/ Adenocarcinoma of Lung - genetics
/ Adenocarcinoma of Lung - mortality
/ Adenocarcinoma of Lung - therapy
/ Adult
/ Age
/ Aged
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ Disease
/ DNA
/ Female
/ Gene Expression Regulation, Neoplastic
/ Health Promotion and Disease Prevention
/ Humans
/ Leukemia
/ Male
/ Mitochondrial Proteins - genetics
/ MTFR2
/ Mutation
/ Neoplasm Recurrence, Local - diagnosis
/ Neoplasm Recurrence, Local - genetics
/ Neoplasm Recurrence, Local - mortality
/ Oncology
/ Tumors
